Drugs / DS-7011a
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05203692 | Feb 2022 → Jan 2023 | systemic lupus erythematosus | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05638802 | Jun 2023 → Apr 2025 | systemic lupus erythematosus | Daiichi Sankyo | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-7011a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05203692 ↗ |
| Action | Inhibit | “antagonistic” NCT05638802 ↗ |
| Modality | Monoclonal antibody | “antagonistic monoclonal antibody” NCT05638802 ↗ |
| Route | Intravenous | “single ascending intravenous (IV) and subcutaneous (SC) doses of DS-7011a” NCT05203692 ↗ |
| Route | Subcutaneous | “single ascending intravenous (IV) and subcutaneous (SC) doses of DS-7011a” NCT05203692 ↗ |
| Target | TLR7 | “anti-Toll-like receptor 7 (TLR7)” NCT05638802 ↗ |